Todd Koelling, MD
Internal Medicine · Ann Arbor, MINPI 1528144573
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $208 of the $248 with a category attached, or 83.9%. Abbott accounts for 83.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $106 and has fallen 62.1% since, to $40 in 2021. That places this record below the midpoint for internal medicine clinicians in MI, where the typical reported total is $183.
Across 3 payments — averaging $82.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$208
- Vifor Pharma, Inc.$40
Across 32 payments — averaging $6665.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$213K
What the payments were for
- Food & beverage$20884%
- Education$4016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $208 |
| Vifor Pharma, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$248 in reported general payments places this provider in the 50th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 106 | $2,394,875 |
| VyndaqelTafamidis Meglumine | 51 | $1,122,270 |
| EliquisApixaban | 232 | $279,993 |
| EntrestoSacubitril/Valsartan | 176 | $279,026 |
| FarxigaDapagliflozin Propanediol | 132 | $162,977 |
| JardianceEmpagliflozin | 61 | $83,720 |
| XareltoRivaroxaban | 45 | $64,126 |
| CellceptMycophenolate Mofetil | 21 | $46,131 |
| Repatha SureclickEvolocumab | 33 | $21,812 |
| Everolimus | 26 | $21,481 |
| Tacrolimus | 163 | $16,217 |
| Mycophenolate Mofetil | 80 | $15,927 |
| VascepaIcosapent Ethyl | 19 | $12,926 |
| Repatha SyringeEvolocumab | 16 | $12,659 |
| PrografTacrolimus | 20 | $7,563 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Ann Arbor
- Terry SmithAnn Arbor$2.3M
- Ulka VaishampayanAnn Arbor$996K
- A FendrickAnn Arbor$347K
- Gazala KhanAnn Arbor$86K
- Michael ValituttoKalamazoo$1.8M
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.